MedTrace Logo

Randomized, Double-Blind Phase 1 Safety and Tolerability Study of Pafuramidine Maleate (DB289) in Healthy Subjects

NCT00619346 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-03-07

No results posted yet for this study

Summary

This is a phase 1 study to establish the safety and tolerability profile of pafuramidine maleate 100 mg BID administered orally for 14 days to healthy subjects

Conditions

  • Healthy

Interventions

DRUG

Placebo

Placebo tablets, BID X 14 days

DRUG

pafuramidine maleate

Pafuramidine maleate, 100 mg tablet BID X 14 days

Sponsors & Collaborators

  • Immtech Pharmaceuticals, Inc

    lead INDUSTRY

Principal Investigators

  • Anina M Van der Bijil, MD · Farmovs-Parexel Clinical Research Organization

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • South Africa

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619346 on ClinicalTrials.gov